APTITUDE HEALTH®

EPICS

Small Cell Lung Cancer (SCLC) in 2022 and Beyond – Region 2

August 17, 2022

Report Contents

EPICS

Meeting Snapshot

EPICS

EPICS

VIRTUAL CLOSED-DOOR ROUNDTABLE

DATE:
August 17, 2022



DISEASE-STATE AND DATA PRESENTATIONS by key experts

INSIGHTS REPORT including postmeeting analyses and actionable recommendations

PANEL: 8 key experts in SCLC in 7 states in the US

SCLC-SPECIFIC DISCUSSIONS on the latest research updates, therapeutic advances, and their application in clinical decision-making

Panel Consisting of 8 US Small Cell Lung Cancer Experts

EPICS

Sonam Puri, MD
University of Utah

Asrar Alahmadi, MBBS
Ohio State University
Comprehensive Cancer Center

Isabel Preeshagul, MD, MS, DO
Memorial Sloan Kettering
Cancer Center

Roy Herbst, MD, PhD
Yale Cancer Center

CHAIR:
Nagashree Seetharamu, MD, MBBS
Donald and Barbara Zucker
School of Medicine

Janakiraman Subramanian, MD
Inova Schar Cancer Institute

Millie Das, MD
Stanford Cancer Center

Mark Socinski, MD
AdventHealth Cancer Institute

APTITUDE HEALTH®

Meeting Agenda

EPICS

Time	Topic	Speaker/Moderator
6.00 PM – 6.05 PM	**Welcome and Introductions**	Nagashree Seetharamu, MD, MBBS
6.05 PM – 6.15 PM	**Biomarkers in SCLC**	Sonam Puri, MD
6.15 PM – 6.30 PM	**Key Questions and Topics for Discussion**	All Faculty
6.30 PM – 6.35 PM	**Key Takeaways**	Sonam Puri, MD
6.35 PM – 6.45 PM	**Recent Progress and Emerging Therapies in Second Line and Beyond**	Mark Socinski, MD
6.45 PM – 7.20 PM	**Key Questions and Topics for Discussion**	All Faculty
7.20 PM – 7.25 PM	**Key Takeaways**	Mark Socinski, MD
7.25 PM – 7.35 PM	**Standards of Care Across the SCLC Treatment Continuum**	Roy Herbst, MD, PhD
7.35 PM – 7.50 PM	**Key Questions and Topics for Discussion**	All Faculty
7.50 PM – 7.55 PM	**Key Takeaways**	Roy Herbst, MD, PhD
7.55 PM – 8.00 PM	**Summary and Meeting Close**	Nagashree Seetharamu, MD, MBBS

APTITUDE HEALTH®

EPICS

Biomarkers in SCLC

Sonam Puri, MD
University of Utah

Current State of Biomarkers in SCLC and Immune Checkpoint Inhibitors

EPICS

BIOMARKERS REPRESENT THE NEXT STEP IN IMPROVING SCLC TREATMENT PATHWAYS

> Biomarkers are needed to develop personalized medicine in SCLC

Subtypes of SCLC (RNA based)

EPICS

SCLC SUBTYPES

[redacted]

Advancement in DNA and Methylome Profiling (DNA based)

EPICS

GENOMIC PROFILING THROUGH DNA TESTING

[redacted]

Chemi F, et al. *Nature*. 2022.
doi:10.1038/s43018-022-00415-9

APTITUDE HEALTH®

Focus on SLFN11 and c-MYC (protein based)

EPICS

SLFN11

Placebo and TMZ

Veliparib and TMZ

TWO PROTEINS AS POTENTIAL BIOMARKERS

> SLFN11: DNA/RNA helicase. High expression levels of SLFN11

APTITUDE HEALTH®

EPICS

Biomarkers in SCLC

Key Takeaways

Discussion Highlight: Biomarkers in SCLC

EPICS

SCLC IS ONE OF THE RARE REMAINING SOLID TUMOR TYPES WHERE THERE IS NO APPROVED COMPANION BIOMARKER

> Currently, biomarkers are not being used in the clinic and are mostly considered in the context of

Dr Puri:
Circulating free DNA is the most promising [test

[redacted]

APTITUDE HEALTH®

EPICS

Recent Progress and Emerging Therapies in Second Line and Beyond

Mark Socinski, MD
AdventHealth Cancer Institute

Treatment Options for Relapsed ES-SCLC

EPICS

NCCN CLINICAL PRACTICE GUIDELINES FOR SECOND-LINE SCLC

> Treatment recommendation depends on CTFI

Efficacy and Safety of Lurbinectedin as Second-Line Therapy in Chinese Patients With Small Cell Lung Cancer: Preliminary Results of a Phase 1 Study

Cheng Y, et al. 2022 ASCO #8580

EPICS

DOSE-EXPANSION ARM

- Dose escalation: from 2.5 to 3.2 mg/m^2 as 1-hr

RESULTS – EFFICACY AND CTFI LENGTH

ATLANTIS Trial: Phase III Randomized Study of Lurbinectedin + DOX in 2L SCLC

Navarro A, et al. 2022 ASCO #8524

EPICS

ATLANTIS trial design

Key eligibility criteria

Experimental arm[a,b]

Primary endpoint

ATLANTIS Clinical Trial: Overall Survival and Posthoc Analysis

Navarro A, et al. 2022 ASCO #8524

EPICS

RESULTS – EFFICACY

1.0

POSTHOC ANALYSIS

> 50 patients completed 10 cycles of lurbi + DOX and

APTITUDE HEALTH®

EPICS

Recent Progress and Emerging Therapies in Second Line and Beyond

Key Takeaways

Discussion Highlight: Lurbinectedin and Other Treatment Options for Second-Line Treatment of SCLC

EPICS

SECOND-LINE TREATMENT OPTIONS FOR SCLC PATIENTS AND THERAPEUTIC LANDSCAPE

> SCLC is viewed by the experts as a graveyard for new drugs, on the basis of the

Discussion Highlight: Lurbinectedin in Second-Line Treatment of SCLC

EPICS

"

BIOMARKERS USE IN THE SECOND LINE

> Experts suggested patients should be tested early, as the disease can progress rapidly. They argued that by the time the disease progresses, there might not be

APTITUDE HEALTH®

EPICS

Standards of Care Across the SCLC Treatment Continuum

Roy Herbst, MD, PhD
Yale Cancer Center

Phase III SKYSCRAPER-02 Primary Results: Tiragolumab in Combination With Atezolizumab + Etoposide in Patients With Untreated ES-SCLC – Efficacy

Charles Rodin, et al. 2022 ASCO #LBA8507

EPICS

STUDY POPULATION (N = 490)

- Phase III trial in ES-SCLC; enrollment criteria

PRIMARY ENDPOINTS

PFS: Primary Analysis Set

APTITUDE HEALTH®

Phase III SKYSCRAPER-02 Primary Results: Tiragolumab in Combination With Atezolizumab + Etoposide in Patients With Untreated ES-SCLC – Efficacy

Charles Rodin, et al. 2022 ASCO #LBA8507

EPICS

SAFETY OVERVIEW

OUTCOME

> Grade 3/4 TRAEs occurred in 52.3% in the

First-Line Pembrolizumab or Placebo Combined With Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-term Follow-up Results

Rudin CM, et al. WCLC 2022 #OA12.06

EPICS

OVERALL SURVIVAL

METHODS (N = 453)

> Selection criteria



APTITUDE HEALTH®

APTITUDE HEALTH®

EPICS

Standards of Care Across the SCLC Treatment Continuum – Discussion of SKYSCRAPER-02

Key Takeaways

Discussion Highlight: Standards of Care Across the SCLC Treatment Continuum

EPICS

RECENT UPDATES AND ADVANCES IN SCLC TREATMENT

> The relevance of trilaciclib support with chemotherapy was discussed